What's New

Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets

SINGAPORE – Media OutReach Newswire – 28 August 2024 – Zuellig Pharma, a leading healthcare solutions company in Asia, has announced an exclusive distribution agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. to launch and commercialise Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the […]

Best Mart 360 Interim Results, Revenue recorded double-digit growth

Proposed an interim dividend of HK11.0 cents per share Highlights: Revenue increased by approximately 10.6% to approximately HK$1,393.7 million as compared with the Corresponding Period Last Year. Gross profit increased by approximately 11.6% to approximately HK$507.9 million as compared with the Corresponding Period Last Year, gross profit margin increased to […]